Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

11th Jul 2013 14:21

RNS Number : 1402J
GlaxoSmithKline PLC
11 July 2013
 



 

Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

 

 

The Administrators of the GlaxoSmithKline 2009 Performance Share Plan (the Plan) notified the Company and the under-mentioned persons on 10 July 2013 of an increase in their notional interests in Ordinary Shares and American Depositary Shares (ADSs). In respect of the 2010, 2011 and 2012 Plan awards, this reflects a reconciliation of notional dividends following a change in Plan administration such that the originally intended number of notional dividends will accrue over the course of the relevant vesting periods. The notional dividends were re-invested on 8 July 2013 at an average price of 1360.50 pence per Ordinary Share and $42.908 per ADS in respect of the balance of 2010 Plan awards, at an average price of 1413.90 pence per Ordinary Share and $44.867 per ADS in respect of 2011 Plan awards and at an average price of 1459.00 pence per Ordinary Share and $46.286 per ADS in respect of 2012 Plan awards.

 

 

Ordinary Shares

ADSs

Sir Andrew Witty

17,912.464

Dr M M Slaoui

5,659.031

Mr S Dingemans

6,669.596

Mr S M Bicknell

1,926.855

Mr R G Connor

96.421

Mrs D P Connelly

2,398.703

Mr S A Hussain

4,912.356

Mr W C Louv

1,646.060

Mr D S Redfern

2,718.988

Ms C Thomas

3,738.227

Mr P C Thomson

1,022.197

Mr D E Troy

3,043.364

Dr P J T Vallance

5,633.601

Ms E Walmsley

3,198.620

Mr C Weber

280.087

Mrs V A Whyte

431.406

 

 

The notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant measurement period.

 

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

 

V A Whyte

Company Secretary

 

11 July 2013

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSXFLFFXDFLBBB

Related Shares:

Glaxosmithkline
FTSE 100 Latest
Value8,632.33
Change89.77